Last updated: February 24, 2026
What Is NDC 65597-0203?
NDC 65597-0203 corresponds to Foscavir (foscarnet sodium injection). It is an antiviral medication indicated for the treatment of herpes simplex virus (HSV) and cytomegalovirus (CMV) infections, particularly in immunocompromised patients. Foscavir is used in cases where other antivirals are ineffective or contraindicated.
Market Size and Demand Drivers
Therapeutic Population
- Estimated patients with CMV retinitis and severe HSV, primarily in immunocompromised populations (e.g., transplant recipients, AIDS patients).
- Growth influenced by rising transplant procedures and HIV prevalence.
- Currently, an estimated 150,000–200,000 patients annually in the U.S. require intravenous antiviral therapy, with Foscavir representing a niche segment.
Competitive Landscape
- Alternatives include ganciclovir, cidofovir, and the newer drug brincidofovir.
- Foscavir has a unique indication profile and intravenous administration route, limiting oral market penetration.
- Market share remains largely confined to specialized hospitals and infusion centers.
Market Trends
- Usage declining in favor of newer agents with better safety profiles.
- Increased adoption in resistant cases or contraindications to other antivirals.
- No recent approvals or labels expanding indications.
Price History and Current Pricing
Historical Price Trends
- The average wholesale price (AWP) has remained relatively stable over the past five years.
- Price per vial (50 mg/mL):
| Year |
Price per vial (USD) |
Notes |
| 2018 |
$1,200 |
Wholesale stability since 2016 |
| 2019 |
$1,200 |
No major price changes |
| 2020 |
$1,200 |
COVID-19 impact minimal; supply stable |
| 2021 |
$1,250 |
Slight increase; inflation-adjusted |
| 2022 |
$1,278 |
Additional minor adjustments |
| 2023 |
$1,300 |
New competitive pressures |
Market Prices
- Pharmacy purchase prices vary; hospital PBM discounts can reduce costs by approximately 20-30%.
- Average selling price (ASP) in outpatient infusion centers approximates $2,500–$3,000 per treatment course, depending on dosage and infusion duration.
Price Projection Outlook
Factors Influencing Future Prices
- Market Demand: Expected slight decline due to newer therapies.
- Competitive Pressure: Market shift toward oral agents lowers demand for IV foscarnet.
- Manufacturing Costs: Stable, with no significant supply chain disruptions reported.
- Regulatory Changes: No recent or upcoming approvals affecting pricing.
Projected Price Range (2024–2028)
| Year |
Estimated Price per vial (USD) |
Comments |
| 2024 |
$1,310–$1,330 |
Minor increases, aligned with inflation |
| 2025 |
$1,330–$1,360 |
Competitive pressures persist |
| 2026 |
$1,340–$1,370 |
Market stabilization anticipated |
| 2027 |
$1,350–$1,390 |
Prices plateauing as market consolidates |
| 2028 |
$1,350–$1,390 |
Stable, barring major shifts in demand or regulation |
Revenue Projections
- Total U.S. market revenue (2023): approximately $200 million.
- Projected annual revenue (2024): $210 million, assuming market volume declines by 5%–10%.
- Long-term revenue will depend on niche market longevity and competition from oral or less invasive therapies.
Strategic Considerations
- Companies positioning Foscavir may face pricing pressure from generic competition.
- Opportunities exist in resistant or special populations.
- Price premiums may persist in hospital settings with limited alternatives.
Key Takeaways
- NDC 65597-0203 (Foscavir) is a niche antiviral with stable pricing, primarily used for resistant infections.
- Market demand will decline slowly due to newer treatments; pricing is expected to remain steady, with minor inflation.
- Market share is concentrated in specialized settings; volume declines are possible but incremental.
- Price projections indicate a slight upward trend in per-vial cost, but market dynamics could alter this trajectory.
- Competition from oral antivirals and generics poses long-term pricing and market share risks.
Frequently Asked Questions
1. What factors most influence Foscavir’s market demand?
Demand depends on the incidence of CMV and HSV in immunocompromised populations, clinician preferences, and availability of competing therapies.
2. How does Foscavir compare price-wise to similar antivirals?
Foscavir’s price per vial (~$1,300) is higher than other IV antivirals like ganciclovir (~$800–$1,000), but it holds unique indications and usage niches.
3. Will generic Foscavir impact prices?
Potential generic entry could reduce prices by 20–30%, especially in hospital procurement settings.
4. Are there upcoming regulatory changes that could affect prices?
No current regulatory updates are anticipated to influence Foscavir pricing or market access.
5. How significant is Foscavir’s role in future antiviral therapy strategies?
Its role remains niche; it is mainly reserved for resistant infections, limiting broader market expansion.
References
- U.S. Food and Drug Administration (FDA). (2022). Foscavir (foscarnet sodium) label.
- IQVIA. (2023). National Prescription Audit.
- Medscape. (2022). Antiviral drug price comparisons.
- MarketLine. (2023). Global Infectious Disease Drugs Market Analysis.
[1] FDA. (2022). Foscavir (foscarnet sodium) label.
[2] IQVIA. (2023). National Prescription Audit.
[3] Medscape. (2022). Antiviral drug price comparisons.
[4] MarketLine. (2023). Global Infectious Disease Drugs Market Analysis.
